Very Low Carbohydrate Diet Effects to GPS, Serum Lactate and TNF Alpha on Colorectal Cancer

July 28, 2017 updated by: Dr. Soetomo General Hospital

Effect of Very Low Carbohydrate Diet to Glasgow Prognostic Score, Serum Lactate and TNF Alpha on Colorectal Cancer Patients With Best Supportive Care

This study examine the effects of very low carbohydrate diet (in which the calories requirements are mostly from fat) to the level of systemic inflammation (measured by Glasgow Prognostic Score), serum lactate and TNF Alpha levels

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This study examine the effects of very low carbohydrate diet (in which the calories requirements are mostly from fat) to the level of systemic inflammation (measured by Glasgow Prognostic Score), serum lactate and TNF Alpha levels. The subjects are colorectal adenocarcinoma patients who were decided by experts to be managed by best supportive care. These patients are not deemed to be suitable for surgical intervention , chemotherapy or radiotherapy anymore. The main treatment is supportive. We would like to examined the effect of very low carbohydrate diet on these patients, in which theoretically tumtor cells of the colorectal adenocarcinoma needed glucose to replicate and increases the systemic inflammation response.

Study Type

Interventional

Enrollment (Anticipated)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosed as colorectal adenocarcinoma pathologically
  • Decided by a digestive surgery consultant to be managed with best supportive care
  • More than 17 years old and capable of making informed consent
  • Karnofsky score > 50% or ECOG performance status <=2
  • No clinical signs of infection, with one or more of these criteria : fever, leukocytosis, local sign of infection (eg.abscess,ulcer)
  • AST < 2 times normal limit
  • ALT < 2 times normal limit
  • Serum Creatinine < 1,5 times normal limit
  • Not pregnant (for women)
  • Able to understand and willing participate and to sign informed consent form
  • No Diabetes Mellitus
  • No fat intolerance
  • No severe malnutrition or cancer cachexia

Exclusion Criteria:

  • Patient is still on other therapy for the tumour
  • Patient with coexisting diseases which prohibits the patient to follow the study protocols

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Very Low Carbohydrate Diet
The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
Other: Very Low Carbohydrate Diet
1 : 4 ratio of carbohydrate to fat of the total daily calories intake
No Intervention: Control
The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glasgow Prognostic Score
Time Frame: Change of baseline Glasgow Prognostic Score on day 21
A score to evaluate systemic inflammation response
Change of baseline Glasgow Prognostic Score on day 21

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum Lactate
Time Frame: Change of baseline Serum Lactate on day 21
Lactate level in blood serum
Change of baseline Serum Lactate on day 21
TNF Alpha
Time Frame: Change of baseline TNF Alpha serum level on day 21
Level of Tumor Necrosis Factor Alpha in the blood serum
Change of baseline TNF Alpha serum level on day 21

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dr. Soetomo General Hospital

Investigators

  • Principal Investigator: Vicky S Budipramana, PhD, RS Dr Sutomo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 5, 2017

Primary Completion (Anticipated)

August 30, 2017

Study Completion (Anticipated)

August 30, 2017

Study Registration Dates

First Submitted

July 16, 2017

First Submitted That Met QC Criteria

July 17, 2017

First Posted (Actual)

July 19, 2017

Study Record Updates

Last Update Posted (Actual)

August 1, 2017

Last Update Submitted That Met QC Criteria

July 28, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DrSoetomoGH

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diet Modification

Clinical Trials on Very Low Carbohydrate Diet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe